Autologous stem cell rescue (ASCT) following high-dose myeloablative chemotherapy is considered to be a therapeutic option for many multiple myeloma (MM) patients; however relapse post ASCT presents a major challenge. The oncolytic potential of reovirus has been previously demonstrated and is currently undergoing phase I monotherapy clinical trials for MM and phase II/III clinical trials for solid tumors. Here we tested the hypothesis that reovirus can successfully purge MM in a murine model that partially recapitulates human MM. RPMI 8226, MM1S, H929 and U266 human myeloma cell lines were exposed to reovirus and oncolysis was assessed. Apheresis product admixed with MM cells was purged with live reovirus (LV) or dead virus (DV) and purging efficacy was monitored via flow cytometry, reverse transcribed-PCR (RT-PCR) and disease relapse in non obese diabetic/severe combined immune deficient (NOD/SCID) mice. Significant LV purging was seen with MM1S, H929 and U266 and the complete ex vivo purging achieved with RPMI 8226 was confirmed by flow cytometry, RT-PCR and absence of disease relapse in vivo. Mice that received LV-purged autografts exhibited 100% survival in comparison to mice that received DV-purged controls. Reovirus's unique ability to kill MM while sparing hematopoietic stem cells places it as an attractive purging agent for MM during ASCT.
INTRODUCTION
Despite improved understanding of multiple myeloma (MM) biology and the advent of novel therapeutics such as thalidomide, revlimid and bortezomib the disease remains incurable. 1 Most MM patients have symptomatic disease at diagnosis and consideration of high-dose chemotherapy followed by autologous hematopoietic SCT (ASCT) is applicable to more than 50% of MM patients. 2 Although high-dose chemotherapy supported by ASCT has improved overall survival and is currently a first-line treatment for many MM patients, disease relapse remains the primary cause of mortality. 3 Therapy-resistant systemic disease and occult clonogenic tumor cells within the autograft are two possible contributors of relapse following high-dose chemotherapy and ASCT. 4 Although the impact of reinfusion of contaminating MM remains unclear, evidence presented in a prospective study by Gertz et al. 5 suggests that MM graft contamination leads to poor outcome following transplantation. Conversely, a report by Ho et al. 6 presents evidence to contradict these results. Although a multicenter randomized trial has shown that MM minimal residual disease (MRD) depletion by CD34-positive cell selection does not improve overall or PFS, 7 recent clinical evidence supports significant differences in PFS of patients with 'low' graft contamination (o4.5 Â 10 5 plasma cells/kg) versus 'high' graft contamination (X4.5 Â 10 5 plasma cells/kg). 8 In addition, syngeneic twin transplantation has shown significantly lower relapse risk than autotransplantation for MM, again suggesting that graft contamination may impact outcome following ASCT. 9, 10 Although CD34 þ cell selection has been used as a purging modality in the clinic, several studies have demonstrated that even after CD34 þ cell selection, MRD could still be detected in MM patient autografts. [11] [12] [13] Evidence presented by Szczepek et al. 14 has shown that CD34 þ cells in MM patient blood could carry IgH VDJ gene rearrangements that may result in relapse. The failure of CD34 þ cell selection to successfully purge autografts of contaminating tumor cells calls for the development of other purging strategies to address this problem. A diversity of ex vivo purging techniques have been described, that is, MoAbs, immunotoxins, CD34 þ cell selection, chemotherapy, photodynamic therapy, ligand toxins and viral-based methods (reviewed by Thirukkumaran et al., 15 Bartee et al. 16 and Yang et al.
17
). The optimal purging method should preferentially destroy contaminating tumor cells while preserving the number and function of normal hematopoietic stem cells, and to date no method has been universally adopted into the clinical setting.
Two recent reports have investigated the feasibility of MM purging in autografts. In a study by Yang et al. 17 PBPC were exposed to rituximab to kill the highly clonogenic CD138 À 20 þ B cells and also to bortezomib to target the CD138 þ plasma cells. The efficacy of purging was tested via flow cytometry and PCR using 16 patient apheresis product (AP) samples and 3-4 log depletion of tumor was noted. The possibility of using the myxoma virus as a purging modality for MM has been demonstrated by Bartee et al. 16 following this study. In this study the myxoma virus was able to kill MM cell lines and spare hematopoietic stem cells under in vitro and in vivo conditions. Although these studies lend valuable insight to novel purging strategies of MM, they fail to address the best assessments of purging efficacy, that is, lack of disease relapse/adverse effects on human stem cells post purging in an in vivo model 17 or survival improvements in vivo post purging.
Oncolytic reovirus is a ubiquitous, non-enveloped doublestranded RNA virus with negligible pathogenicity in humans. 15 Reovirus's extensive preclinical efficacy has been documented by our group and others, and is presently undergoing phase II/III clinical trial testing. Viral sensitivity is likely mediated via several oncogenic signaling pathways that allow reovirus oncolysis of cancer cells. 18 The inherent complexity of genetic abnormalities found in cancer cells creates an environment beneficial to reovirus therapy.
A recent study by Steinbrunn et al. 19 indicates that mutated ras and constitutively active Akt define discrete oncogenic pathways in MM, which independently contribute to survival. In addition to the common N-ras and K-ras mutations that are frequently found in MM, many other diverse cancer-promoting signaling pathways such as the MEK/ERK, PI3K/Akt, mTOR/p70S6-kinase and NF-kB pathways have been identified 20 that may promote reovirus lytic infection, thus enhancing the range of potential treatable patients. In susceptible cancers, reovirus is thought to take advantage of these activated neoplastic signaling pathways in a p53-independent/-dependent manner and engage in NF-kB activation/trafficking, autocrine release of the TNF-related apoptosis-inducing ligand and activation of endoplasmic reticular stress (reviewed by Thirukkumaran et al. 21 and Kelly et al. 22 ). Recently we have shown the oncolytic potential of reovirus against a large cohort of MM cell lines and patient tumor, 18 and demonstrated that reovirus exposure of CD34 þ progenitor stem cells does not abrogate their repopulation or differentiation in vivo. A phase I monotherapy clinical trial for MM has also been initiated recently in the United States of America. In the present study, we show that reovirus could be used as an effective purging agent for MM utilizing an in vivo transplantation model, thus providing preclinical data for a future phase I clinical trial of MM purging.
MATERIALS AND METHODS

Cell lines
RPMI 8226, MM1S, U266 and H929 were obtained from the American Type Culture Collection (Manassas, VA, USA) and RPMI 8226 and MM1S-GFP þ cells were kindly provided by Drs Linda Pilarsky (University of Alberta, Canada) and Nizar Bahlis (University of Calgary, Canada), respectively. MM cells were maintained in RPMI 1640 medium (Gibco BRL, Burlington, Ontario, Canada) containing 10% fetal bovine serum. In addition, the medium was supplemented with G148 (100 mg/mL) or puromycin (2 mg/ mL) for RPMI 8226-GFP and MM1S-GFP cells, respectively.
Reovirus
Reovirus serotype 3 (strain Dearing) was propagated in L929 cells and purified as previously described. 23 Human MM cell lines were infected with either, live reovirus (LV) or UV-inactivated reovirus (dead reovirus, DV) at a multiplicity of infection (MOI) of 40 plaque forming units/cell for DV treatments or 20, 40 or 100 MOI for LV treatments for 24, 48 and 72 h. Reovirus cytotoxicity was monitored using the water soluble tetrazolium salt (WST) (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2 H-5-tetrazolio]-1,3-benzene disulfonate) assay. 18 For cytopathic effects, MM cells were treated with 40 MOI of LV or DV for 48 h and photographed under a fluorescent microscope (Zeiss Axiovert 40 CFL, Zeiss, Toronto, Ontario, Canada). We have previously shown no significant difference between DV or no virus treatments for a variety of tumors as well as CD34 þ stem cells and AP. 23 Therefore DV was chosen as the most stringent control for all reovirus experiments.
AP and ex vivo reovirus purging of autografts All APs utilized in the present study were obtained from patients registered at the Tom Baker Cancer Centre, Calgary, Canada after informed consent. AP cells were washed in PBS and MM cells were admixed with AP in RPMI 1640 medium supplemented with 10% fetal bovine serum to result in 2-6% tumor burden. Cell admixtures were either treated with LV or DV (40 MOI per total cell population) and incubated for up to 72 h. At 0 and 60 or 72 h of purging, samples were taken from admixed cell populations and intact MM-GFP þ cells were evaluated using flow cytometry. For the MRD assessment of U266 and H929, cells were immunophenotyped and enumerated for bright CD38 þ /138 þ expression using flow count beads. The efficacy of purging was further validated by RT-PCR (see below). To assess the sensitivity of MRD detection by flow cytometry, AP cells were admixed with RPMI 8226-GFP þ cells to result in tumor to AP cell ratios of 1:10 7 -10 6 :10 7 and GFP þ cells were enumerated.
RT-PCR and PCR for MRD detection
For the detection of MM MRD post purging, RNA was extracted from AP cells/RPMI8226-GFP þ cells (10 Â 10 6 ) using Trizol reagent (Invitrogen, Carlsbad, CA, USA) as per manufacture's instructions. One microgram of total cellular RNA was reverse transcribed in a final volume of 20 mL using SuperScript III reverse transcriptase (Invitrogen). Nested PCR against enhanced GFP was performed as previously reported. 24 Primers used were: 5 0 -CACCGGGGTGGTGCCCATCC-3 0 (sense) and 5 0 -GGCGGCGGTCA CGAACTCCAG-3 0 (antisense) for the first round and 5 0 -TGAACCGCATC GAGCTGAAG-3 0 (sense) and 5 0 -CAGCAGGACCATGTGATCG-3 0 (antisense) for the nested round. Sensitivity of RT-PCR was evaluated by admixing RPMI 8226-GFP þ cells with AP cells to result in tumor: AP cell ratios of 1:10 6 -10 6 :10 6 . RT-PCR was performed with the RNA extracted. The PCR product was separated in 1.5% agarose gels containing ethidium bromide and the 'GFP' bands were visualized.
Animals
Six-to eight-week-old male severe combined immune deficient/non obese diabetic (SCID/NOD) mice were purchased from Jackson Laboratories, Bar Harbor, Maine, USA. The animals were housed in a sterile animal facility with food and water ad libitum. All procedures were reviewed and approved by The University of Calgary Animal Care Committee.
Functional quantitation of reovirus purging efficacy in a SCID/NOD mouse transplantation model SCID/NOD mice were sublethally irradiated (1.25 Gy total body g-irradiation from a (137) Cs source) and given an i.p. injection of 50 mL of anti-asialo GM1 Ab for elimination of natural killer cells. On day 0, LV-or DV-purged AP (as described above) was washed gently 3 Â in PBS to remove residual reovirus and injected intravenously to animals via their tail vein (approximately 5 Â 10 6 AP cells admixed with 2% RPMI 8226-GFP þ cells in a total volume of 200 mL). To prevent reovirus-related morbidity and inflammatory vasculitis in the extremities seen in immunocompromised animals (never seen in nude mice or immunocompetent mice), all animals were treated with purified polyclonal rabbit anti-reovirus serum (100 mg, tail vein) on days 14, 21 and 28. Mice were assessed for weight loss, grooming performance, signs of visible tumor and overall survival three times per week. At the time of death (or animals exhibiting more than 20% weight loss that require euthanasia) the animals were assessed for disease relapse.
Sacrificed animals were subjected to whole-body fluorescence imaging for detection of GFP þ MM lesions in the skeleton and s.c. tissues. For each sacrificed DV-purged animal, a corresponding LV-purged animal was sacrificed between days 21 and 30 for comparison of disease relapse. Liver, spleen, lung, brain, heart, small and large intestines were analyzed for metastatic deposits by GFP fluorescence. Femurs from animals were flushed in PBS and the collected BM cells were analyzed for GFP fluorescence and human CD38 þ /138 þ staining. For mouse survival analysis, two separate experiments were performed to determine the reproducibility of the experimental design/results. (N ¼ 4 animals each for DV, LV for experiment 1 and N ¼ 6 animals each for DV, LV for experiment 2). Survival was monitored for an arbitrary period of 110 days in all experiments.
Statistical methods
Average relative percent viability values for each cell line, along with their corresponding standard errors, were plotted at 24, 48 and 72 h post reovirus infection. At 72 h, these values were evaluated using a one-way analysis of variance to assess statistical differences between the LV levels.
Kaplan-Meier (K-M) estimates of survival curves for the two groups of mice who received either LV-or DV-purged autographs were calculated and an exact log-rank test statistic was calculated to compare survival Multiple myeloma purging with reovirus CM Thirukkumaran et al curves. 25 All analyses were carried out using the statistical software program R (Boston, Massachusetts, USA).
RESULTS
Reovirus exhibits sensitivity toward MM cell lines
Of the four MM cell lines tested, RPMI 8226 displayed the most sensitivity to LV at all MOIs tested, whereas DV treatment did not have any effect on the MM cell viability in any cell line (Figure 1) . MM1S, U266 and H929 displayed o20% cell viability at 72 h post viral infection and no significant differences in the dose of live virus treatment was detected at this time (F-test P-values all 40.158 ). Therefore for all experiments a virus dose of 40 MOI was utilized. As depicted in Figure 2 all cell lines exhibited significant cytopathic effects with LV but not DV treatment.
Ex vivo purging of reovirus depletes MRD in autografts In order to assess purging efficacy of reovirus, we utilized GFPtagged RPMI 8226 and MM1S as well as wild-type U266 and H929 myeloma cells. Preliminary experiments revealed no significant differences in reovirus killing of wild-type or GFP-tagged RPMI 8226 or MM1S. When patient AP was spiked with these MM cells and purged with reovirus, flow cytometric analysis revealed complete loss of admixed RPMI 8226 in AP at 60 h post purging with LV, whereas DV-purged autografts resulted in increased cell numbers due to proliferation (Figure 3a) . MM1S showed 70-fold (2log) depletion of myeloma cells post purging with reovirus, whereas U266 and H929 showed up to 12-fold depletion of contaminating tumor cells (Figures 3c-e) .
To further confirm the complete purging seen with reovirus with RPMI8226 cells, we utilized RT-PCR analysis of GFP þ sequences. As depicted in Figure 3b the absence of GFP þ bands in LV-purged autografts and the presence of GFP þ bands in DVpurged autografts confirmed the above findings (Figure 3b When we investigated the effect of ex vivo purging in an in vivo model, all six mice injected with DV-purged autografts showed symptoms of malignancy (weight loss, neurological deficits) between days 20 and 35 and had to be sacrificed. As shown in Figure 5a , multiple GFP þ MM lesions were seen in all DV-purged mice, with the majority of lesions seen in the axial skeleton, skull and isolated plasmacytoma-like lesions. In contrast, all six mice infused with LV-purged autografts were clinically disease free and had no visible GFP þ lesions detected. Mouse BM analyzed for GFP þ MM cells demonstrated viable tumor in DV-purged mice but not in any of the LV-purged mice (Figure 5b) . Finally, K-M survival analysis showed significant (P ¼ 0.0012) improvements in survival (Figure 5c ). DV-purged animals had to be euthanized as per animal protocols of University of Calgary between days 20 and 40 owing to tumor burden, whereas the LV-purged animals survived without toxicity until arbitrarily euthanized at day 110. This experiment has been repeated with an additional four animals/group and yielded identical results (data not presented).
DISCUSSION
In the present study, the feasibility of using reovirus, a benign environmental RNA virus as a potential purging agent for MM that could be applicable to a clinical setting is presented. Recently we have shown the possibility of using reovirus as a systemic therapeutic for MM where six of the seven human MM cell lines and five of the seven patient specimens tested demonstrated reovirus sensitivity. 18 In addition, importantly, we also have demonstrated the lack of reovirus effects on hematopoietic stem cells and their lineage differentiation in vitro and in vivo. 18, 23 Expanding on these findings, we tested the hypothesis that reovirus could be used as a successful ex vivo purging agent for MM, as autograft contamination may lead to disease relapse and the subsequent death of patients.
The previously described purging methodologies are either inefficient, toxic to hematopoietic stem cells or are too arduous to be considered appropriate for clinical practice. 15 Although CD34 þ cell selection has been used as a purging modality in the clinic, this has been shown in randomized trials not to benefit patients from PFS or overall survival. 7 Deola et al. 11 have demonstrated that even after CD34 þ cell selection, MRD could still be detected in MM patient autografts. This possibly may be due to the fact that some CD34 þ stem cells circulating in MM patient blood could carry IgH VDJ gene rearrangements that will lead to MM relapse as shown by Szczepek et al.
14 Previously, we have shown that AP carrying 1-10% tumor burden of primary patient specimens of various lymphomas purged with reovirus resulted in successful elimination of malignant cells in vitro. 23 To examine reovirus's purging ability on MM MRD, we utilized an ex vivo purging model where patient AP cells were admixed with MM cells. Successful purging was confirmed in vitro using two methodologies; RT-PCR and flow cytometry for RPMI 8226, the most reovirus-sensitive cell line. Both these procedures have the ability to detect one MM cell in 10 4 -10 7 tumor cells in AP, and results confirmed efficient purging with LV. Among the three moderately reovirus-sensitive cell lines, up to 70-fold depletion of tumor burden (2log) was seen with MM1S, whereas up to 12-fold reduction in tumor in autografts was seen with H929 and U266. These results were achieved with high levels of graft contamination, and over exemplify the clinical scenario where the maximum tumor burden usually encountered in graft contamination is o2%. The discrepancy of reovirus sensitivity toward these cell lines could not be correlated with their genetic/ molecular aberrations. 18 Currently, next generation sequencing of these cell lines is underway in our laboratory and we anticipate that this will shed more light on teasing out these differences of virus sensitivities.
A more robust assessment of purging efficacy is the lack of disease relapse in a transplanted animal model accompanied by evidence of normal in vivo hematopoietic stem cell repopulating ability post ex vivo purging. DV-purged autografts transplanted into NOD/SCID mice showed disease relapse and required euthanasia due to tumor burden; however, mice transplanted with LV-purged autografts maintained health for the duration of the experiment (110 days). All mice with DV-purged autografts showed GFP þ lesions in the bone including the appendicular and axial skeleton mimicking the osteotropic nature of MM in patients.
Mice showing hind leg paralysis likely was due to vertebral bone lesions, and spinal cord involvement was the primary reason for euthanasia. In addition to homing to the BM milieu, GFP þ MM was also detected as s.c. lesions (reminiscent of plasmacytomas) in DV-purged autograft recipient mice representing advanced disease.
An important aspect of an ideal purging strategy is the lack of effect on hematopoietic stem cells within the graft in terms of their functional capacity and lineage differentiation post purging. Previously we have demonstrated negligible adverse effects of reovirus on isolated CD34 þ human stem cells or AP under in vitro conditions using three methodologies. First [
35 S]-methionine and SDS-PAGE analysis of apheresis cells incubated in the presence of reovirus up to 60 h did not affect normal host (AP) protein synthesis. Even after G-CSF stimulation reovirus did not affect stem cells. 23 Second, isolated stem cells at the time of harvest from patient apheresis product cultured in StemSpam medium followed by exposure to reovirus at an MOI of 40 did not affect the stem cell population and terminal differentiation. Third, the inability of reovirus to affect long-term colony forming units was demonstrated by plating stem cells incubated with reovirus up to 5 days in methyl cellulose-based medium. Colony formation in methylcellulose increased with prolonged incubation irrespective of whether they have been exposed to reovirus or not. 21, 23 More recently, we have shown that human stem cells isolated from AP, treated with LV or DV for 3 days and transplanted into NOD/SCID mice showed similar repopulation and lineage differentiation, 18 confirming reovirus's lack of effect on hematopoietic stem cells.
Although numerous studies have reported viral-based methodologies as purging agents for breast, myeloma, leukemia, neuroblastoma cancer cell lines and/or ex vivo tumors, 15 only three investigations have shown both stem cell engraftment and absence of relapse in murine models. [26] [27] [28] In contrast to these reports, the striking features of utilizing reovirus as a purging agent are as follows: enhanced efficacy; lack of effect on stem cell number/ function; tumor selectivity, eliminating the need to clear residual virus from the autograft prior to reinfusion in patients; minimal autograft manipulation; and relative ease of manufacturing and storage. Reovirus is not associated with significant toxicities in immunocompetent animals nor in the 560 patients treated with reovirus to date. Therefore, the need to remove reovirus post purging is likely unnecessary and in fact may be beneficial from a systemic therapeutic point of view. The knowledge that most adults have already been exposed to reovirus earlier, as evidenced by seroconversion and the availability of passive immunization with reovirus anti-sera, tempers the small concern regarding infusion of residual reovirus into a immunosuppressed host.
In conclusion, this study represents the first utilization of reovirus as an ex vivo purging agent for MM patients undergoing ASCT that could lead to bench-to-bedside translation in the future. Of the four MM cell lines that were tested for reovirus purging efficacy, one demonstrated complete purging, whereas the others showed a significant tumor reduction. As less tumor burden in an autograft could lead to an advantage in PFS, 8 reovirus purging may be considered as an option for many MM patients. In an era where a personalized approach to medicine is sought, one might even envision that MM represents a malignancy where BM aspirates could easily be withdrawn from patients and tested for reovirus sensitivity before initiating either a treatment regimen or purging strategy. In addition, this study constitutes a potential framework for extension of these findings to other hematological malignancies as well. 
